Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Inventory (2018 - 2025)

Historic Change in Inventory for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Q3 2025 value amounting to $5.6 million.

  • Ultragenyx Pharmaceutical's Change in Inventory rose 12380.0% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 1962.27%. This contributed to the annual value of $11.2 million for FY2024, which is 6171.72% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Change in Inventory stood at $5.6 million for Q3 2025, which was up 12380.0% from -$208000.0 recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Change in Inventory's 5-year high stood at $5.6 million during Q3 2025, with a 5-year trough of -$474000.0 in Q1 2021.
  • In the last 5 years, Ultragenyx Pharmaceutical's Change in Inventory had a median value of $2.0 million in 2023 and averaged $2.0 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Change in Inventory crashed by 21812.08% in 2021 and then soared by 178297.87% in 2022.
  • Ultragenyx Pharmaceutical's Change in Inventory (Quarter) stood at $990000.0 in 2021, then soared by 324.75% to $4.2 million in 2022, then crashed by 53.48% to $2.0 million in 2023, then grew by 25.56% to $2.5 million in 2024, then skyrocketed by 127.81% to $5.6 million in 2025.
  • Its Change in Inventory stands at $5.6 million for Q3 2025, versus -$208000.0 for Q2 2025 and $763000.0 for Q1 2025.